Skip to main content
. 2016 Apr;8(4):a019521. doi: 10.1101/cshperspect.a019521

Figure 5.

Figure 5.

The development status of epigenetic drugs. KDMi, lysine demethylase inhibitor; KMTi, lysine methyltransferase inhibitor; HATi, histone acetyltransferase inhibitor; HDACi, histone deacetylase inhibitor; BETi, bromodomain and extracarboxy terminal domain inhibitor; DNMTi, DNA methyltransferase inhibitor.